NCT05463952进行中（未招募）1 期
A PHASE I, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ARV-471 (PF-07850327), A SINGLE AGENT IN JAPANESE PARTICIPANTS WITH ER+/HER2-LOCALLY ADVANCED OR METASTATIC BREAST CANCER
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Pfizer
- 入组人数
- 6
- 试验地点
- 3
- 主要终点
- Number of Participants With Dose Limiting Toxicity (DLTs) During First Treatment Cycle
研究概览
简要总结
The purpose of this clinical trial is to learn about the safety, tolerability, Pharmacokinetics (PK), and preliminary efficacy of ARV-471 as monotherapy in Japanese participants with ER+/HER2- locally advanced or metastatic breast cancer (mBC).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants (women and men) at least 20 years of age at the time of signing the informed consent.
- •Histological or cytological diagnosis of ER+/HER2- advanced breast cancer that is metastatic, recurrent, or locally advanced unresectable breast cancer.
- •Participants who are resistant to standard therapy or for which no standard therapy is available or have received.
- •Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the Infromed Consent Document (ICD) and in this protocol.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or
- •Adequate Bone Marrow or Coagulation Function.
- •Adequate Renal Function, defined as an estimated creatinine clearance ≥60 mL/min as calculated using the method standard for the institution.
- •Adequate Liver Function.
- •Participants with brain metastases must meet all the specified conditions.
- •Resolution of acute effects of any prior therapy to either baseline severity or CTCAE version 5.0 Grade ≤1.
排除标准
- •Participants with any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix, Bowen's disease.
- •Participants sustaining major surgery defined as a complex procedure performed under regional or general anesthesia with a recovery period of at least 4 weeks prior to study enrollment.
- •Known or suspected hypersensitivity or severe allergy to active ingredient/excipients of ARV-
- •Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- •Radiation therapy within 4 weeks of first dose of study drug or prior irradiation to >25% of the bone marrow. Palliative radiation for the alleviation of pain due to bone metastasis will be allowed during the study.
- •Concurrent administration of medications, foods or herbal supplements that are strong inhibitors or inducers of CYP3A4 and drugs with a known risk of causing Torsade de Pointes or QT interval prolongation. Prior use of strong CYP3A inhibitors and drugs with a known risk of causing Torsade de Pointes or QT interval prolongation must be stopped 7 days before enrollment and strong CYP3A inducers must be stopped 14 days before enrollment.
- •Prior treatment with ARV-
- •Systemic anticancer therapy chemotherapy or endocrine therapy within 14 days prior to study entry (6 weeks for mitomycin C or nitrosoureas). If the last immediate anticancer treatment contained an antibody-based agent(s) (approved or investigational), then an interval of 28 days or 5 half-lives (whichever is shorter) of the agent(s) prior to receiving the study intervention treatment is required.
- •Participants who have initiated therapy with bone-modifying agents (bisphosphonates, denosumab, or similar) within 14 days of enrollment.
- •Previous high-dose chemotherapy requiring stem cell rescue.
- •Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry. A participant may be eligible even if they are in the follow-up phase of an investigational study as long as they haven't received treatment in the study for 5 half lives of the agents.
- •Serum pregnancy test (for females of childbearing potential) positive at screening and/or a breastfeeding participant.
- •Participants with active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and known Human Immunodeficiency Virus (HIV) or Acquired Immunodeficiency Syndrome (AIDS)-related illness.
- •Baseline standard 12 lead electrocardiogram (ECG) that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results.
- •Any of the following in the previous 12 months: myocardial infarction, long QT syndrome, Torsade de Pointes, clinically important atrial or ventricular arrhythmias, serious conduction system abnormalities, unstable angina, coronary/peripheral artery bypass graft, symptomatic CHF, New York Heart Association class III or IV, cerebrovascular accident, transient ischemic attack, symptomatic pulmonary embolism, and/or other clinical significant episode of thrombo-embolic disease. Ongoing cardiac dysrhythmias of NCI CTCAE Grade ≥2, atrial fibrillation of any grade . If a participant has a cardiac rhythm device/pacemaker placed and QTcF >470 ms, the participant may be considered eligible. Participants with cardiac rhythm device/pacemaker must be discussed in detail with the sponsor to judge eligibility.
- •History of symptomatic cardiac valve disease.
- •Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery.
研究组 & 干预措施
vepdegestrant
Experimental
Daily oral dosages of vepdegestrant
干预措施: vepdegestrant (Drug)
结局指标
主要结局
Number of Participants With Dose Limiting Toxicity (DLTs) During First Treatment Cycle
时间窗: Cycle 1 (28 days)
DLT was defined as any adverse event (AE) or abnormal laboratory value which were related to ARV-471 and assessed as unrelated to disease, disease progression, intercurrent illness or concomitant medications/therapies occurring during the first 28 days of treatment that met at least 1 of the study specified criteria.
次要结局
- Number of Participants With AEs and Serious AEs (SAEs)- All Causalities and Treatment Related(Day 1 of study treatment up to 35 days after last dose of study treatment (approximately 1.5 years))
- Number of Participants With Laboratory Hematology Results by Maximum National Cancer Institute Common Terminology Criteria (NCI-CTCAE) Grade(During study treatment, approximately 1.5 years)
- Number of Participants With Laboratory Chemistry Results by Maximum NCI-CTCAE Grade(During study treatment, approximately 1.5 years)
- Area Under the Plasma Concentration-Time Curve From Time Zero to Time Tau (AUCtau) of ARV 471 and ARV-473(Through the end of the study treatment (approximately 1.5 years))
- Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of ARV-471 and ARV-473(Through the end of the study treatment (approximately 1.5 years))
- Maximum Observed Plasma Concentration (Cmax) of ARV-471 and ARV-473(Through the end of the study treatment (approximately 1.5 years))
- Time to Reach Maximum Concentration (Tmax) of ARV-471 and ARV-473(Through the end of the study treatment (approximately 1.5 years))
- Terminal Elimination Half-Life (t1/2) of ARV-471 and ARV-473(Through the end of the study treatment (approximately 1.5 years))
- Metabolite Ratio for Cmax (MRCmax)(Through the end of the study treatment (approximately 1.5 years))
- Metabolite Ratio for AUCtau (MRAUCtau)(Through the end of the study treatment (approximately 1.5 years))
- Lowest Concentration Observed During the Dosing Interval (Cmin) of ARV-471 and ARV-473(Through the end of the study treatment (approximately 1.5 years))
- Pre-dose Plasma Concentration (Ctrough) of ARV-471 and ARV-473(Through the end of the study treatment (approximately 1.5 years))
- Apparent Total Clearance (CL/F) of ARV-471(Through the end of the study treatment (approximately 1.5 years))
- Apparent Volume of Distribution (Vz/F) of ARV-471(Through the end of the study treatment (approximately 1.5 years))
- Effective Half-Life Based on Accumulation Ratio (t½Eff) of ARV-471 and ARV-473(Through the end of the study treatment (approximately 1.5 years))
- Accumulation Ratio (Rac) Based on AUC of ARV-471 and ARV-473(Through the end of the study treatment (approximately 1.5 years))
- Objective Response Rate (ORR)(From start of study treatment until disease progression or death due to any cause (approximately 1.5 years))
- Clinical Benefit Response (CBR)(From start of study treatment until disease progression or death due to any cause (approximately 1.5 years))
- Progression Free Survival (PFS)(From start of study treatment until disease progression or death due to any cause or censoring date (approximately 1.5 years))
- Duration of Response (DOR)(From the first documentation of objective tumor response to the first documentation of objective tumor progression or to death due to any cause (approximately 1.5 years))
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
MEDI2228 in Subjects With Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Multiple MyelomaNCT03489525MedImmune LLC107
已完成
1 期
A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in ChinaBreast CancerNCT05732428Pfizer9
招募中
1 期
Study of GEC255 in Subjects With Advanced Solid Tumors With KRAS p.G12C MutationAdvanced Solid TumorsNCT05768321GenEros Biopharma Hangzhou Ltd70
已完成
1 期
An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid MalignanciesAdvanced Solid MalignanciesNCT05469919AstraZeneca12
已完成
1 期
A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast CancerER+ HER2- Advanced Breast CancerNCT04541433AstraZeneca10